of the two control groups (MSib and URD) were significantly different from the clofarabine-conditioned groups (Clo-CY or Clo-CY*).
In order to establish the relative myelosuppressive properties of the Clo-CY regimen vs Flu-CY, we compared the time taken in achieving ANC4500 in two groups failing to achieve at least 10% donor engraftment by day 12 --18 (our initial assessment of chimerism). Six such patients treated with Flu-CY and similar immunoprophylaxis (one had been excluded from the above analysis because of having received 45 Â 10 6 donor CD34 cells/kg body weight) achieved ANC4500 at days 8 --10 (mean 9 days). Those five patients not engrafting stably after Clo-CY recovered to ANC4500 at 8 --24 days (mean day 17 --one, in fact, expired without recovery of neutrophils on day 18). Although these groups were not statistically different in time taken for neutrophil recovery (P ¼ 0.092---Mann --Whitney test), it seems safe to conclude that the Clo-CY regimen is at least as myelosuppressive as Flu-CY.
From the above data we conclude that Clo-CY, although significantly myelosuppressive, is insufficiently immunosuppressive to yield reliable engraftment in most patients receiving allo-SCT. Other groups have published effective regimens utilizing clofarabine in allotransplant conditioning, 6 --10 but all of these investigators employed co-administered agents that are far more myelosuppressive (high dose melphalan 6, 7 or BU 8 --10 ) or immunosuppressive (alemtuzumab 6 ) than that employed in our study. Although the CY dose, which we used was smaller than that in the Flu-CY-treated patients we report above, the regimen is at least as myelosuppressive as Flu-CY. Clo-CY, as described here, employed a lower CY dose than used Flu-CY, thus we cannot formally exclude the possibility that the difference in engraftment seen relates to the CY dose. It seems most reasonable to conclude that clofarabine is significantly less immunosuppressive than fludarabine; however, formal proof of this hypothesis will require other studies. This has, however, other implications for clofarabine use in non-transplant settings. Unlike the experience with fludarabine, 1 there have been no reports of transfusion-associated GVHD associated with its use, thus irradiation of blood products after its use may be unnecessary (but has not been recommended). For now, it seems most logical not to rely on clofarabine as an immunosuppressive agent for promotion of allogeneic stem cell engraftment.
